AstraZeneca Results Presentation Deck
Lynparza
The globally-leading PARP¹ inhibitor
$m
13
600
500
400
300
200
100 -
Lynparza
33% sales growth to $0.5bn
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Fur Q3 2019
Product sales at actual exchange rates; changes
at CER and for Q1 2021, unless stated otherwise.
1. Poly ADP ribose polymerase.
Q4 2019
Lynnarza
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
As
●
E
Approvals 81 (ovarian), 79 (breast), 59
(pancreatic) and 55 (prostate cancer)
AstraZeneca
US +28% (47% of total)
Growth driven by use in prostate
cancer
Europe +33%
Growth from 1st-line OC2, prostate
EMs +54%
Expanded China NRDL supported OC
2. Ovarian cancer.
EROW +22%
Japan: +17%. c.14% Q2 2020 price cut.
OC uptake; emerging in other cancers
$
Q3 2017
Lynparza
collaboration revenue
da
Q4 2017
Q1 2018
2018
Q4 2018
Q2 2018
Q3
Q1 2019
US-28859 4/19
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2
2020
Q3 2020
Q4
2020
Q1 2021
Collaboration
exchange rates.
revenue at actual
Collaboration with Merck & Co., Inc., Kenilworth,
NJ, US, known
side the US and Canada. $3.1bn revenue recorded; $4.6bn future potential.
$m
as MSD out-
1,000
800
600
400
200
0
$
THE
TRE
FOR PView entire presentation